He completed his pre-doctoral studies at the State University of New York at Stony Brook, and holds a Ph.

[citation needed] His research interests including respiratory diseases, Hepatitis C, HIV, and focus on anti-infective therapeutic strategies.

[2] He left Institut Pasteur in 2006 to become the President of CombinatoRx-Singapore,[3] the infectious disease subsidiary of CombinatoRx (NASDAQ:CRXX), established in 2005 in collaboration with Bio*One Capital in Singapore.

Ralf Altmeyer left CombinatoRx-Singapore in summer 2009 subsequent to the acquisition of the company by Forma Therapeutics.

Ralf Altmeyer also holds the position of adjunct professor at Griffith University of Australia, Institute of Glycomics.